[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1962

Sympatholytic Agent SKF No. 6890Effects on Rabbit, Normal Human, and Glaucomatous Eyes

Author Affiliations

From the Research and Clinical Departments of the Wills Eye Hospital and the Department of Ophthalmology, Graduate School of Medicine of the University of Pennsylvania.

Arch Ophthalmol. 1962;67(5):600-607. doi:10.1001/archopht.1962.00960020600014

Introduction  Adrenergic activity plays a part in the maintenance of normal arterial pressure and intraocular pressure.1,2 Its participation in the development of arterial hypertension and ocular hypertension has long been suspected. Mechanisms aimed at reduction of this activity have been employed as therapeutic tools in essential hypertension and primary glaucoma. One such measure is the use of adrenergic blocking agents, which combine at adrenoceptive sites of autonomic effector cells and thereby prevent effects of adrenergic (sympathetic) nerve impulses or of circulating sympathomimetic amines of endogenous (adrenal medulla) or exogenous (drugs) origin.3,4Considerable interest was aroused in TM 10 (2,6-dimethyl phenoxy) ethyl] trimethyl ammonium bromide because of its principal property of blockade of adrenergic nerves without antagonism of the peripheral actions of exogenous epinephrine or levarterenol. It effectively lowered the blood pressure of hypertensive patients, but its additional parasympathomimetic properties were pronounced. The practical utility of this drug was

First Page Preview View Large
First page PDF preview
First page PDF preview